Table 1.
Patients´ characteristics
| Characteristic | n = 32 |
|---|---|
| Sex n (%) | |
| male | 21 (66) |
| female | 11 (34) |
| Age (years) | |
| median | 63 |
| range | 44–81 |
| Stadium n (%) | |
| localized | 10 (31) |
| metastasized | 22 (69) |
| Grading n (%) | |
| G2, G3 | 22 (69) |
| G1 | 7 (22) |
| Gxa | 3 (9) |
| Cycles of doxorubicin/olaratumab administered n (%) | |
| 1 to 5 | 23 (72) |
| 6 to 8 | 9 (28) |
| median no. of cycles | 4 |
| Exposure to doxorubicin | |
| median cumulative dose (mg/m2) | 300 |
| range (mg/m2) | 75–600 |
| Proportion of patients with delay of therapy due to toxicity/infection n (%) | 4 (12,5) |
| Patients with previous treatment lines n (%) | |
| 0 | 25 (78) |
| ≥ 1 | 7 (32) |
| Response n (%) | |
| PR | 4 (13) |
| SD | 7 (22) |
| PD | 21 (66) |
| Performance status (ECOG) n (%) | |
| 0 | 14 (44) |
| 1 | 16 (50) |
| 2 | 2 (6) |
| Pattern of metastases n (%) | |
| lung only | 3 (9) |
| multiple | 6 (19) |
| Site of primary tumor n (%) | |
| extremity | 8 (25) |
| retroperitoneum | 8 (25) |
| trunc | 14 (4) |
| head | 1 (3) |
| uterus | 1 (3) |
| Site of metastasis n (%) | |
| lung | 6 (19) |
| liver | 4 (13) |
| bone | 2 (6) |
| other | 7 (22) |
PR partial remission; SD stable disease; PR progressive disease
ano formal grading available, but with clear histologic and radiologic features of high grade sarcoma